menu
    • menu
    [{"orgOrder":0,"company":"Secura Bio","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"BMS-986345","moa":"DNMT1","graph1":"Oncology","graph2":"Phase I","graph3":"Secura Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Secura Bio \/ Secura Bio","highestDevelopmentStatusID":"6","companyTruncated":"Secura Bio \/ Secura Bio"},{"orgOrder":0,"company":"Secura Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Secura Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Secura Bio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Secura Bio \/ Undisclosed"},{"orgOrder":0,"company":"Secura Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Secura Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Secura Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Secura Bio \/ Undisclosed"},{"orgOrder":0,"company":"Secura Bio","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Divestment","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Secura Bio","amount2":0.31,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.47999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Secura Bio \/ Secura Bio","highestDevelopmentStatusID":"15","companyTruncated":"Secura Bio \/ Secura Bio"},{"orgOrder":0,"company":"Secura Bio","sponsor":"Verastem Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Divestment","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Secura Bio","amount2":0.47999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.47999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Secura Bio \/ Secura Bio","highestDevelopmentStatusID":"15","companyTruncated":"Secura Bio \/ Secura Bio"},{"orgOrder":0,"company":"Secura Bio","sponsor":"Secura Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Secura Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Secura Bio \/ Secura Bio","highestDevelopmentStatusID":"8","companyTruncated":"Secura Bio \/ Secura Bio"}]

    Find Clinical Drug Pipeline Developments & Deals by Secura Bio

    Menu

    Secura Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Secura Bio

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Secura Bio

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Duvelisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib for the Treatment of Patients with P...

                            Details : COPIKTRA (duvelisib) is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first US approved dual inhibitor of PI3K-delta and PI3K-gamma, two enzymes known to help support the growth and survival of malignant cells.

                            Product Name : Copiktra

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 09, 2023

                            Lead Product(s) : Duvelisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Secura Bio

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Secura Bio

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-986345

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Moffitt Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

                            Details : BMS-986345 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Non-Hodgkin.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            October 04, 2021

                            Lead Product(s) : BMS-986345

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Moffitt Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Secura Bio

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Secura Bio

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Duvelisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Glenn J. Hanna

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC

                            Details : Duvelisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 27, 2021

                            Lead Product(s) : Duvelisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Glenn J. Hanna

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Secura Bio

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Secura Bio

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Duvelisib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Secura Bio's COPIKTRA® Receives Positive CHMP Opinion for the Treatment of Relapsed and Refractory CLL and Re...

                            Details : COPIKTRA is an oral dual inhibitor of the PI3K-delta and gamma pathways, which are involved in the proliferation, growth, and migration of malignant cells and are thought to play a role in the formation and maintenance of a supportive tumor microenvironm...

                            Product Name : Copiktra

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 01, 2021

                            Lead Product(s) : Duvelisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Secura Bio

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Secura Bio

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Duvelisib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Verastem Oncology

                            Deal Size : $481.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Verastem Oncology Announces Closing of COPIKTRA® (duvelisib) Sale to Secura Bio

                            Details : Verastem’s sale of COPIKTRA to Secura Bio follows Verastem’s previously announced new strategic direction focused on development of its RAF/MEK inhibitor (VS-6766) and FAK inhibitor (defactinib) program in KRAS mutant (KRASmt) solid tumors.

                            Product Name : Copiktra

                            Product Type : Miscellaneous

                            Upfront Cash : $70.0 million

                            September 30, 2020

                            Lead Product(s) : Duvelisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Verastem Oncology

                            Deal Size : $481.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Secura Bio

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Secura Bio

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Duvelisib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Verastem Oncology

                            Deal Size : $311.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA® (duvelisib) Rights to Secura Bio

                            Details : Verastem’s sale of COPIKTRA follows the Company’s previously announced strategic direction to focus on maximizing the broad potential of its RAF/MEK inhibitor (VS-6766) and FAK inhibitor (defactinib) program in KRAS mutant (KRASmt) solid tumors.

                            Product Name : Copiktra

                            Product Type : Miscellaneous

                            Upfront Cash : $70.0 million

                            August 10, 2020

                            Lead Product(s) : Duvelisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Verastem Oncology

                            Deal Size : $311.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth